Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Combination Therapy Considerations BPC-157 has been investigated in combination with other therapeutic peptides and conventional treatments with apparent synergistic or additive effects
The key point: BPC-157 should only be considered with guidance from a licensed provider who understands peptide therapy, safety, and current regulations
Contains 0.9% (9 mg/mL) of benzyl alcohol added as a bacteriostatic preservative.
Standalone cagrilintide (RENEW program) has no NDA filing yet
Unlike traditional injectable peptides, MK-677 is taken orally and provides sustained elevation of GH/IGF-1 levels over a 24-hour period
BENEFITS Tissue repair studied for accelerating recovery in tendon, ligament, and muscle models Gut protection explored for protective effects on gastric and intestinal lining Angiogenesis linked to promotion of new blood vessel formation in healing tissues Anti-inflammatory associated with reduction of inflammatory markers in preclinical research Neuroprotection investigated for potential nerve regeneration pathways WHAT RESEARCHERS LOOK AT Angiogenesis and vascularization in connective tissue recovery Fibroblast migration and collagen deposition pathways Gastric and intestinal lining protection in animal models Neuroprotective and anti-inflammatory signaling cascades Synergistic effects when combined with TB-500 (Thymosin Beta-4) QUICK SPECS Form: Lyophilized peptide powder Net per vial: 20 mg Purity: 99% (HPLC verified) Identity: MS-verified (per COA) Storage: 28C, protect from light and moisture Reconstitution: Use bacteriostatic water (sold separately) IDENTITY BASICS Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Molecular Formula: CHNO Molecular Weight: 1419.53 g/mol CAS: 137525-51-0 WHY CHOOSE DURHAM PEPTIDES FOR BPC-157
US$ 24.17
US$ 21.24
US$ 25.26
US$ 24.05
US$ 22.67
US$ 25.10
US$ 28.77
US$ 23.25
